Julian Harrison
Stock Analyst at BTIG
(1.02)
# 3,672
Out of 4,876 analysts
37
Total ratings
32.26%
Success rate
-13.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $4.78 | +736.82% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $11.40 | +268.42% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $13.47 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $22.99 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.73 | +421.74% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.46 | +447.95% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $1.63 | +390.80% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $14.68 | +315.53% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $4.20 | +257.14% | 2 | Sep 10, 2024 | |
| LQDA Liquidia | Maintains: Buy | $29 → $25 | $13.19 | +89.54% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $55.22 | -7.64% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $7.41 | +480.30% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $15.73 | +154.29% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $11.26 | +86.50% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $43.37 | -0.85% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $3.67 | +8.99% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.92 | +16,207.89% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $47.59 | -24.35% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $287.61 | - | 2 | Feb 11, 2022 |
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $4.78
Upside: +736.82%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $11.40
Upside: +268.42%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $13.47
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $22.99
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.73
Upside: +421.74%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.46
Upside: +447.95%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $1.63
Upside: +390.80%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $14.68
Upside: +315.53%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $4.20
Upside: +257.14%
Liquidia
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $13.19
Upside: +89.54%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $55.22
Upside: -7.64%
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $7.41
Upside: +480.30%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $15.73
Upside: +154.29%
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $11.26
Upside: +86.50%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $43.37
Upside: -0.85%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $3.67
Upside: +8.99%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.92
Upside: +16,207.89%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $47.59
Upside: -24.35%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $287.61
Upside: -